Health 2.0 announces keynotes and preliminary program

11 - 12 May 2016, Barcelona, Spain.
Health 2.0 announces keynote speakers and preliminary program for the 7th Annual Health 2.0 Europe Conference. After a highly successful conference last May in Barcelona, the International event series will be back for another 3 full days discussing challenges faced by the healthcare system and showcasing the latest technologies and innovations that are making an impact.

Health 2.0 Europe is a truly international conference, bringing speakers from all across the world to discuss and find solutions to those healthcare challenges from a global perspective. It will bring together 600 digital health champions including entrepreneurs, executives, thoughtleaders, investors, physicians, and patients over insightful keynotes, interactive workshops, animated round tables and more than 50 rapid fire live demo.

The keynote speakers already confirmed are:

  • Esther Dyson, active business angel and board member in various healthcare companies, she was named by Forbes as one of the most powerful American business woman. She will share her vision on the healthcare challenges and how to tackle them.
  • Dr. Rafael Grossmann, the surgeon who practiced the 1 st live surgery using Google Glass will showcase exclusive innovative solutions he is using and that are supporting both healthcare professionals and enhancing patients' experience.
  • Damien Marmion, Global Head of Health at AXA, will share AXA’s vision as an insurance pioneer in reimbursing digital health solutions and the role of reimbursement in accelerating adoption of digital health in Europe.
  • Dr. Julio Mayol, chief medical and innovation officer at San Carlos Hospital in Madrid, will give his vision on how hospitals should look at health 2.0 solutions and present their successful Smart Health Lab, an initiative launched to design, develop and implement innovative solutions.
  • Pēteris Zilgalvis, Head of Unit for eHealth and Well Being in DG CONNECT, will share the vision and strategic plan of the European Commission on getting a more dynamic digital health ecosystem, involving every stakeholder.

Health 2.0 Europe takes into account all the different stakeholders of the digital health ecosystem. Some of the topics that we will be discussing this year:

  • Solutions for hospitals and healthcare professionals
  • Building a new framework for Health 2.0 adoption in the clinic setting
  • Building Blocks to a Dynamic Health 2.0 Ecosystem in Europe
  • Health 2.0 Applications in Emerging Markets
  • Data Analytics: Structuring Information for DecisionMaking
  • Choosing your Digital Health Accelerator
  • Pharma 2.0: Going Beyond the Pill
  • Frontiers of Health 2.0: What's Next?
  • Power to the patient
  • Technology promoting behaviour change and healthy
  • Health 2.0 transforming the daily mission of nurses
  • Who will pay for Health 2.0? An investor's discussion
  • Reimbursement players, trends, criteria and processes
  • SHUSH topics and the famous unmentionables
  • From Health to WellBeing: the rise of wearables and consumer interfaces

For further information and to register, please visit:
https://goo.gl/IVCb3P

Early bird prices end on 18th March. Book you ticket now using the code EHNEWS16 to get 15% discount.

About Health 2.0
Health 2.0 is the premiere showcase and catalyst for the advancement of new health technologies. Through a global series of conferences, developer competitions, and leading market intelligence, Health 2.0 drives the innovation and collaboration necessary to transform health and health care. In addition to our flagship event held in the Bay Area each Fall, we host events around the world including in Europe, Latin America and India, and new for 2015 Korea and Japan.

Most Popular Now

Scientists uncover SARS-CoV-2-specific T cell immu…

The study by scientists from Duke-NUS Medical School, in close collaboration with the National University of Singapore (NUS) Yong Loo Lin School of Medicine, Singapore Ge...

Researchers call for worldwide biosurveillance net…

The emergence of COVID-19 is a powerful reminder of how unchecked wildlife trade can lead to the spillover spread of viruses between wildlife and humans. Understanding th...

Common FDA-approved drug may effectively neutraliz…

A common drug, already approved by the Food and Drug Administration (FDA), may also be a powerful tool in fighting COVID-19, according to research published this week in ...

New study supports remdesivir as COVID-19 treatmen…

The news about remdesivir, the investigational anti-viral drug that has shown early promise in the fight against COVID-19, keeps getting better. This week researchers at ...

Drug linked to 45% lower risk of dying among COVID…

Critically ill COVID-19 patients who received a single dose of a drug that calms an overreacting immune system were 45% less likely to die overall, and more likely to be ...

Neutralizing antibodies in the battle against COVI…

An important line of defence in the fight against the new corona virus SARS-CoV-2 is the formation of neutralising antibodies. These can eliminate the intruders and have ...

Pfizer and BioNTech granted FDA Fast Track designa…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced that two of the companies' four investigational vaccine candidates from their BNT162 mRNA-bas...

Sanofi and Regeneron provide update on Kevzara® (s…

Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that the U.S. Phase 3 trial of Kevzara® (sarilumab) 400 mg in COVID-19 patients requiring mechanical v...

GSK and CureVac announce strategic mRNA technology…

GlaxoSmithKline plc (LSE/NYSE: GSK) and CureVac announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialis...

Novartis launches first-of-its-kind not-for-profit…

Novartis announced a new initiative to help patients in low-income and lower-middle-income countries (LIC; LMIC) access affordable medicines to treat the major symptoms o...

COVID-19 vaccine AZD1222 showed robust immune resp…

Interim results from the ongoing Phase I/II COV001 trial, led by Oxford University, showed AZD1222 was tolerated and generated robust immune responses against the SARS-Co...

Neutralizing antibodies isolated from COVID-19 pat…

Researchers at Columbia University Irving Medical Center have isolated antibodies from several COVID-19 patients that, to date, are among the most potent in neutralizing ...